[go: up one dir, main page]

PE20021011A1 - Derivados quinazolinicos como inhibidores de la rho-quinasa - Google Patents

Derivados quinazolinicos como inhibidores de la rho-quinasa

Info

Publication number
PE20021011A1
PE20021011A1 PE2002000224A PE2002000224A PE20021011A1 PE 20021011 A1 PE20021011 A1 PE 20021011A1 PE 2002000224 A PE2002000224 A PE 2002000224A PE 2002000224 A PE2002000224 A PE 2002000224A PE 20021011 A1 PE20021011 A1 PE 20021011A1
Authority
PE
Peru
Prior art keywords
rho
kinase
inhibitors
alkyl
quinazolinamine
Prior art date
Application number
PE2002000224A
Other languages
English (en)
Inventor
Dhanapalan Nagarathnam
Uday Khire
Jianxing Shao
Xiao-Gao Liu
Stephen Boyer
Donald Bankston
Olaf Weber
Mark Lynch
Barry Hart
Chunguang Wang
Davoud Asgari
Original Assignee
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Corp filed Critical Bayer Corp
Publication of PE20021011A1 publication Critical patent/PE20021011A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE REFIERE A COMPUESTOS DE FORMULA I DONDE Y ES =N-, =CR17; X ES -(CH2)x-, -O-(CH2)n-, ENTRE OTROS; n ES 0-3; x ES 0-3; p ES 0-3; a Y c ES -CR5=, -N=, -NR6-; A ES UN GRUPO DE 3-20 ATOMOS; R1, R6-R11 SON H, ALQUILO C1-C6; R2-R5 SON H, ALQUILO C1-C10, ALQUENILO C2-C10, ENTRE OTROS; R17 ES H, ALQUILO C1-C6, CN. SE REFIERE TAMBIEN A UN PROCEDIMIENTO PARA LA PREPARACION. SON COMPUESTOS PREFERIDOS 2-(2,4-DICLOROFENIL)-N-(1H-INDAZOL-5-IL)-4-QUINAZOLINAMINA, N-(1H-INDAZOL-5-IL)-2-(2-QUINOXALINIL)-4-QUINAZOLINAMINA, 5-FLUORO-N-(1H-INDAZOL-5-IL)-2-(2-METILFENIL)-4-QUINAZOLINAMINA, ENTRE OTROS. LOS COMPUESTOS MENCIONADOS SON INHIBIDORES DE LA RHO-QUINASA Y SON UTILES PARA EL TRATAMIENTO DE ENFERMEDADES CARDIACAS CORONARIAS
PE2002000224A 2001-03-23 2002-03-22 Derivados quinazolinicos como inhibidores de la rho-quinasa PE20021011A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27797401P 2001-03-23 2001-03-23
US31534101P 2001-08-29 2001-08-29

Publications (1)

Publication Number Publication Date
PE20021011A1 true PE20021011A1 (es) 2003-02-01

Family

ID=26958819

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002000224A PE20021011A1 (es) 2001-03-23 2002-03-22 Derivados quinazolinicos como inhibidores de la rho-quinasa

Country Status (19)

Country Link
US (3) US20030125344A1 (es)
EP (1) EP1370553B1 (es)
JP (1) JP4329003B2 (es)
AR (1) AR035791A1 (es)
AT (1) ATE325795T1 (es)
AU (1) AU2002250394A1 (es)
CA (1) CA2441492C (es)
CY (1) CY1107475T1 (es)
DE (1) DE60211317T2 (es)
DK (1) DK1370553T3 (es)
ES (1) ES2264477T3 (es)
HN (1) HN2002000067A (es)
MX (1) MXPA03008658A (es)
MY (1) MY134783A (es)
PE (1) PE20021011A1 (es)
PT (1) PT1370553E (es)
TW (1) TWI261055B (es)
UY (1) UY27224A1 (es)
WO (1) WO2002076976A2 (es)

Families Citing this family (167)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4320705B2 (ja) * 2001-03-23 2009-08-26 バイエル コーポレイション Ｒｈｏキナーゼ阻害剤
MY134783A (en) * 2001-03-23 2007-12-31 Bayer Healthcare Llc Rho-kinase inhibitors
EP1403255A4 (en) * 2001-06-12 2005-04-06 Sumitomo Pharma RHO KINASE INHIBITORS
CA2472619A1 (en) * 2002-01-10 2003-07-24 Bayer Corporation Fused pyrimidine derivates as rho-kinase inhibitors
US7645878B2 (en) * 2002-03-22 2010-01-12 Bayer Healthcare Llc Process for preparing quinazoline Rho-kinase inhibitors and intermediates thereof
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
CN100425241C (zh) 2002-08-29 2008-10-15 参天制药株式会社 由Rho激酶抑制剂和前列腺素类物质构成的青光眼治疗剂
JP2006521398A (ja) 2003-03-28 2006-09-21 サイオス・インコーポレーテツド ＴＧＦβの二−環式ピリミジン阻害剤
GB0307333D0 (en) * 2003-03-29 2003-05-07 Astrazeneca Ab Therapeutic agent
AU2004230928B2 (en) * 2003-04-09 2010-12-02 Exelixis, Inc. Tie-2 modulators and methods of use
WO2004105757A2 (en) * 2003-05-29 2004-12-09 Schering Aktiengesellschaft Use of rho-kinase inhibitors in the treatment of aneurysm and cardiac hypertrophy
US20080146562A1 (en) * 2003-08-08 2008-06-19 Ulysses Pharmaceutical Products Inc., Halogenated quinazolinyl nitrofurans as antibacterial agents
US7410974B2 (en) * 2003-08-08 2008-08-12 Ulysses Pharmaceutical Products, Inc. Halogenated Quinazolinyl nitrofurans as antibacterial agents
AU2004272348B2 (en) 2003-09-16 2008-09-04 Astrazeneca Ab Quinazoline derivatives as tyrosine kinase inhibitors
WO2005034866A2 (en) * 2003-10-06 2005-04-21 Glaxo Group Limited Preparation of 1, 6, 7- trisubstituted azabenzimidazoles as kinase inhibitors
ES2387780T3 (es) * 2003-10-06 2012-10-01 Glaxosmithkline Llc Preparación de azabencimidazoles 1,6-disustituidos como inhibidores de quinasas
EP1689393A4 (en) * 2003-10-06 2008-12-17 Glaxo Group Ltd PREPARATION OF 1,7-DISUBSTITUTED AZABENZIMIDAZOLES AS KINASE INHIBITORS
KR101163800B1 (ko) 2003-10-15 2012-07-09 산텐 세이야꾸 가부시키가이샤 신규 인다졸 유도체
GB0326459D0 (en) 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
DE10357510A1 (de) * 2003-12-09 2005-07-07 Bayer Healthcare Ag Heteroarylsubstituierte Benzole
UA86614C2 (ru) 2004-01-23 2009-05-12 Амген Инк Соединение, которое имеет активность ингибитора киназ, фармацевтическая композиция, которая включает указанное соединение, и их применение для приготовления лекарственного препарата
CA2553433A1 (en) 2004-01-23 2005-08-11 Amgen Inc. Quinoline quinazoline pyridine and pyrimidine compounds and their use in the treatment of inflammation angiogenesis and cancer
CN1914182B (zh) 2004-02-03 2011-09-07 阿斯利康(瑞典)有限公司 喹唑啉衍生物
DE102004017438A1 (de) * 2004-04-08 2005-11-03 Bayer Healthcare Ag Hetaryloxy-substituierte Phenylaminopyrimidine
JP4991527B2 (ja) * 2004-06-01 2012-08-01 ユニバーシティ オブ バージニア パテント ファンデーション 二つの部分からなる低分子量の癌および血管新生の抑制剤
WO2005120509A1 (en) 2004-06-04 2005-12-22 Amphora Discovery Corporation Quinoline- and isoquinoline-based compounds exhibiting atp-utilizing enzyme inhibitory activity, and compositions, and uses thereof
JP2007269629A (ja) * 2004-06-21 2007-10-18 Astellas Pharma Inc キナゾリン誘導体
BRPI0516751A (pt) 2004-09-30 2008-09-16 Tibotec Pharm Ltd pirimidinas bicìclicas que inibem hcv
CA2587642C (en) 2004-11-30 2013-04-09 Amgen Inc. Substituted heterocycles and methods of use
CA2593718A1 (en) * 2004-12-31 2007-05-31 Gpc Biotech Ag Napthyridine compounds as rock inhibitors
JP2006219395A (ja) * 2005-02-09 2006-08-24 Koei Chem Co Ltd ビピリジン化合物の製造方法
US7534796B2 (en) 2005-02-18 2009-05-19 Wyeth Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor
US7538113B2 (en) 2005-02-18 2009-05-26 Wyeth 4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
US7582634B2 (en) 2005-02-18 2009-09-01 Wyeth 7-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
JP4966958B2 (ja) * 2005-03-14 2012-07-04 ノイロサーチ アクティーゼルスカブ カリウムチャネル調節剤及び医療における使用
KR20070122194A (ko) 2005-03-25 2007-12-28 티보텍 파마슈티칼즈 리미티드 Ｈｃｖ의 헤테로비사이클릭 저해제
CR9465A (es) 2005-03-25 2008-06-19 Surface Logix Inc Compuestos mejorados farmacocineticamente
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
AR056347A1 (es) 2005-05-12 2007-10-03 Tibotec Pharm Ltd Uso de compuestos de pteridina para fabricar medicamentos y composiciones farmaceuticas
US7531542B2 (en) 2005-05-18 2009-05-12 Wyeth Benzooxazole and benzothiazole antagonists of gonadotropin releasing hormone receptor
US7582636B2 (en) 2005-05-26 2009-09-01 Wyeth Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of Gonadotropin Releasing Hormone receptor
PT1899322E (pt) 2005-06-28 2009-11-09 Sanofi Aventis Derivados de isoquinolina como inibidores de rho-cinase
EP1932841B1 (en) 2005-08-30 2014-01-01 Asahi Kasei Pharma Corporation Sulfonamide compound
CA2620818A1 (en) 2005-09-02 2007-03-08 Astellas Pharma Inc. Amide derivatives as rock inhibitors
EP2001480A4 (en) * 2006-03-31 2011-06-15 Abbott Lab Indazole CONNECTIONS
TW200815398A (en) * 2006-06-08 2008-04-01 Ube Industries A novel indazole derivative having spirocyclic structure in the side chain
WO2007146230A2 (en) * 2006-06-14 2007-12-21 Merck & Co., Inc. Non-nucleoside reverse transcriptase inhibitors
EP1921070A1 (de) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
MX2009006081A (es) * 2006-12-08 2009-06-17 Irmc Llc Compuestos y composiciones como inhibidores de cinasa de proteina.
EP2537830A1 (en) 2006-12-08 2012-12-26 Irm Llc Compounds and compositions as protein kinase inhibitors
WO2008079945A2 (en) * 2006-12-20 2008-07-03 University Of South Florida Rock inhibitors and uses thereof
CA2677336A1 (en) 2007-02-06 2008-08-14 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, pharmaceutical compositions containing these compounds, the use thereof and processes for the preparation thereof
US8415372B2 (en) 2007-02-27 2013-04-09 Asahi Kasei Pharma Corporation Sulfonamide compound
CA2679263A1 (en) 2007-02-28 2008-09-04 Asahi Kasei Pharma Corporation Sulfonamide compound
JP5234825B2 (ja) 2007-07-02 2013-07-10 旭化成ファーマ株式会社 スルホンアミド化合物及びその結晶
CN103931608B (zh) 2007-08-29 2016-02-03 千寿制药株式会社 促进角膜内皮细胞粘附的药剂
ME01461B (me) 2008-02-07 2014-04-20 Boehringer Ingelheim Int Spirociklični heterocikli, ljekovi koji sadrže navedeno jedinjenje, njihova primjena i postupak za njihovu proizvodnju.
WO2009138781A1 (en) 2008-05-13 2009-11-19 Astrazeneca Ab Fumarate salt of 4- (3-chloro-2-fluoroanilino) -7-methoxy-6- { [1- (n-methylcarbamoylmethyl) piperidin- 4-yl] oxy}quinazoline
JP5539351B2 (ja) 2008-08-08 2014-07-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング シクロヘキシルオキシ置換ヘテロ環、これらの化合物を含有する医薬、およびそれらを生成するための方法
CN101463014B (zh) * 2008-12-26 2013-07-10 复旦大学 二芳基苯并嘧啶类衍生物及其药物组合物和用途
US20120202793A1 (en) * 2009-03-09 2012-08-09 Paul Sweetnam Rho kinase inhibitors
US9109245B2 (en) 2009-04-22 2015-08-18 Viacyte, Inc. Cell compositions derived from dedifferentiated reprogrammed cells
EP3904505A1 (en) 2009-04-22 2021-11-03 Viacyte, Inc. Cell compositions derived from dedifferentiated reprogrammed cells
BR112012008848A2 (pt) 2009-10-16 2019-09-24 Scripps Research Inst composição, e, método in vitro ou ex vivo para induzir células de mamífero não-pluripotente em células tronco pluripotentes induzidas
US8415155B2 (en) 2009-10-19 2013-04-09 Cellular Dynamics International, Inc. Cardiomyocyte production
WO2011062765A2 (en) * 2009-11-17 2011-05-26 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties
AR079814A1 (es) 2009-12-31 2012-02-22 Otsuka Pharma Co Ltd Compuestos heterociclicos, composiciones farmaceuticas que los contienen y sus usos
EP2528606B1 (en) 2010-01-28 2014-09-24 Alexander Levitzki Quinazoline-based t cell proliferation inhibitors
EP2566477B1 (en) * 2010-05-07 2015-09-02 GlaxoSmithKline Intellectual Property Development Limited Amino-quinolines as kinase inhibitors
EP2582794B2 (en) 2010-06-15 2024-04-24 FUJIFILM Cellular Dynamics, Inc. Generation of induced pluripotent stem cells from small volumes of peripheral blood
AR083339A1 (es) 2010-10-05 2013-02-21 Purdue Pharma Lp Compuestos de quinazolina como bloqueadores de los canales de sodio
KR102703637B1 (ko) 2010-12-22 2024-09-05 페이트 세러퓨틱스, 인코포레이티드 단세포 분류 및 iPSC의 증강된 재프로그래밍을 위한 세포 배양 플랫폼
CA2829131C (en) 2011-03-04 2018-11-20 Glaxosmithkline Intellectual Property (No.2) Limited Amino-quinolines as kinase inhibitors
US9487752B2 (en) 2011-03-30 2016-11-08 Cellular Dynamics International, Inc. Priming of pluripotent stem cells for neural differentiation
JP6121658B2 (ja) * 2011-06-29 2017-04-26 大塚製薬株式会社 治療用化合物、及び関連する使用の方法
CA2841165A1 (en) 2011-07-11 2013-01-17 Cellular Dynamics International, Inc. Methods for cell reprogramming and genome engineering
TWI547494B (zh) 2011-08-18 2016-09-01 葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之胺基喹唑啉類
LT2788472T (lt) 2011-12-06 2019-04-10 Astellas Institute For Regenerative Medicine Kryptingos diferenciacijos būdas, skirtas ragenos endotelio ląstelių gamybai
EP3553169B1 (en) 2011-12-28 2021-11-03 Kyoto Prefectural Public University Corporation Normalization of culture of corneal endothelial cells
EP2628482A1 (en) 2012-02-17 2013-08-21 Academisch Medisch Centrum Rho kinase inhiitors for use in the treatment of neuroblastoma
WO2013137491A1 (ja) 2012-03-15 2013-09-19 国立大学法人京都大学 人工多能性幹細胞から心筋および血管系混合細胞群を製造する方法
WO2013151186A1 (ja) 2012-04-06 2013-10-10 国立大学法人京都大学 エリスロポエチン産生細胞の誘導方法
AR092529A1 (es) 2012-09-13 2015-04-22 Glaxosmithkline Llc Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
WO2014080291A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Biaryl derivatives as bromodomain inhibitors
WO2014080290A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Cyclic amines as bromodomain inhibitors
KR20150096794A (ko) 2012-12-21 2015-08-25 제니쓰 에피제네틱스 코포레이션 브로모도메인 저해제로서의 신규한 헤테로사이클릭 화합물
WO2014127214A1 (en) 2013-02-15 2014-08-21 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
AU2014219024B2 (en) 2013-02-20 2018-04-05 KALA BIO, Inc. Therapeutic compounds and uses thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
RU2662810C2 (ru) 2013-02-21 2018-07-31 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Хиназолины в качестве ингибиторов киназы
US8859286B2 (en) 2013-03-14 2014-10-14 Viacyte, Inc. In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (PEC) and endocrine cells
AU2014248167B2 (en) 2013-04-03 2019-10-10 FUJIFILM Cellular Dynamics, Inc. Methods and compositions for culturing endoderm progenitor cells in suspension
CA2909230C (en) 2013-04-12 2021-06-15 Kyoto University Method for inducing alveolar epithelial progenitor cells
SG11201510201PA (en) 2013-06-11 2016-01-28 Univ Kyoto Method for producing renal progenitor cells and drug comprising the same
WO2015004534A2 (en) * 2013-06-21 2015-01-15 Zenith Epigenetics Corp. Novel substituted bicyclic compounds as bromodomain inhibitors
SG11201510409QA (en) 2013-06-21 2016-01-28 Zenith Epigenetics Corp Novel bicyclic bromodomain inhibitors
US10908161B2 (en) 2013-07-30 2021-02-02 Kyoto Prefectural Public University Corporation Corneal endothelial cell marker
AU2014298051B2 (en) 2013-07-31 2018-11-15 Zenith Epigenetics Ltd. Novel quinazolinones as bromodomain inhibitors
EP3031905A4 (en) 2013-08-07 2017-04-26 Kyoto University Method for producing pancreatic hormone-producing cell
EP3042951B1 (en) 2013-09-05 2019-02-20 Kyoto University New method for inducing dopamine-producing neural precursor cells
WO2015054317A1 (en) 2013-10-07 2015-04-16 Kadmon Corporation, Llc Rho kinase inhibitors
ES2847755T3 (es) 2013-10-31 2021-08-03 Kyoto Prefectural Public Univ Corp Fármaco terapéutico que comprende un inhibidor de la señal de TGF-beta para enfermedades relacionadas con la muerte celular del retículo endoplásmico en el endotelio corneal
AU2014342042B2 (en) 2013-11-01 2017-08-17 KALA BIO, Inc. Crystalline forms of therapeutic compounds and uses thereof
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CN105814195A (zh) 2013-11-27 2016-07-27 京都府公立大学法人 层粘连蛋白应用于角膜内皮细胞培养
WO2015112739A1 (en) * 2014-01-22 2015-07-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compounds and method for treating parp1-deficient cancers
CN120536341A (zh) 2014-03-04 2025-08-26 菲特治疗公司 改良的重编程方法和细胞培养平台
ES2939807T3 (es) 2014-03-21 2023-04-27 Fujifilm Cellular Dynamics Inc Producción de neuronas dopaminérgicas del mesencéfalo y métodos para su utilización
EP3147353B1 (en) 2014-05-21 2022-03-30 Kyoto University Method for producing pancreatic blast cells and pancreatic disease treatment agent containing pancreatic blast cells
EP3161127A4 (en) 2014-06-27 2018-06-06 The Regents of the University of California Cultured mammalian limbal stem cells, methods for generating the same, and uses thereof
CN105367555B (zh) * 2014-08-07 2019-06-25 广东东阳光药业有限公司 取代的杂芳基化合物及其组合物和用途
CA2966303A1 (en) 2014-12-01 2016-06-09 Zenith Epigenetics Ltd. Substituted pyridines as bromodomain inhibitors
WO2016087936A1 (en) 2014-12-01 2016-06-09 Zenith Epigenetics Corp. Substituted pyridinones as bromodomain inhibitors
US10292968B2 (en) 2014-12-11 2019-05-21 Zenith Epigenetics Ltd. Substituted heterocycles as bromodomain inhibitors
EP3233846A4 (en) 2014-12-17 2018-07-18 Zenith Epigenetics Ltd. Inhibitors of bromodomains
US10711249B2 (en) 2014-12-26 2020-07-14 Kyoto University Method for inducing hepatocytes
US11021468B2 (en) 2015-04-01 2021-06-01 Rigel Pharmaceuticals, Inc. TGF-ß inhibitors
EP4088719A1 (en) 2015-10-13 2022-11-16 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods and pharmaceutical compositions for the treatment of retinal capillary non-perfusion
WO2017064119A1 (en) 2015-10-13 2017-04-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of retinal capillary non-perfusion
CA3001917A1 (en) 2015-10-16 2017-04-20 Fate Therapeutics, Inc. Platform for the induction & maintenance of ground state pluripotency
TW202344686A (zh) 2015-10-30 2023-11-16 美國加利福尼亞大學董事會 從幹細胞產生t細胞之方法及使用該t細胞之免疫療法
EP3416658B1 (en) 2016-02-15 2023-03-22 Kyoto Prefectural Public University Corporation Human functional corneal endothelial cell and application thereof
JP7011260B2 (ja) 2016-04-22 2022-02-10 国立大学法人京都大学 ドーパミン産生神経前駆細胞の製造方法
WO2018035214A1 (en) 2016-08-16 2018-02-22 Cellular Dynamics International., Inc. Methods for differentiating pluripotent cells
US10336767B2 (en) 2016-09-08 2019-07-02 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US10392399B2 (en) 2016-09-08 2019-08-27 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US10253036B2 (en) 2016-09-08 2019-04-09 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CN106518790B (zh) * 2016-11-02 2019-01-15 河南省商业科学研究所有限责任公司 一种2,4-二氯喹唑啉的合成方法
JP2020503377A (ja) 2016-12-13 2020-01-30 ベータ セラピューティクス プロプライアタリー リミティド ヘパラナーゼ阻害剤及びそれの使用
US11787783B2 (en) 2016-12-13 2023-10-17 Beta Therapeutics Pty Ltd Heparanase inhibitors and use thereof
BR112019024637A2 (pt) 2017-05-25 2020-06-16 Kyoto University Método para produzir células progenitoras renais, célula progenitora renal, organoide renal, composição farmacêutica, e, agente terapêutico para uma doença renal.
CN110582489B (zh) * 2017-06-30 2023-10-27 北京泰德制药股份有限公司 Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
CN110582491B (zh) 2017-06-30 2023-09-29 北京泰德制药股份有限公司 Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
US10329282B2 (en) 2017-06-30 2019-06-25 Beijing Tide Pharmaceutical Co., Ltd. Rho-associated protein kinase inhibitor, pharmaceutical composition comprising the same, as well as preparation method and use thereof
EP3675861A4 (en) * 2017-09-01 2021-01-06 Kadmon Corporation, LLC ALPHA SUPERWINDING PROTEIN KINASE INHIBITORS ("COILED-COIL") ASSOCIATED WITH RHO
EP3708662A4 (en) 2017-11-10 2021-08-25 Regenesis Science Co., Ltd. METHOD FOR PRODUCING A CULTIVATED CELL, AND METHOD FOR PRODUCING A THERAPEUTIC AGENT FOR SPINAL CORD INJURY DISEASE
US11739326B2 (en) 2017-11-14 2023-08-29 Massachusetts Eye And Ear Infirmary RUNX1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition
JPWO2019124488A1 (ja) 2017-12-21 2020-12-17 参天製薬株式会社 セペタプロストとＲｈｏキナーゼ阻害剤との組み合わせ医薬
EP3733837A4 (en) 2017-12-28 2021-10-06 Kaneka Corporation AGENT PROMOTING CELL AGGREGATION
US20210062139A1 (en) 2017-12-28 2021-03-04 Kaneka Corporation Cell aggregation suppressor
WO2019131940A1 (ja) 2017-12-28 2019-07-04 株式会社カネカ 多能性幹細胞凝集抑制剤
CN111788303B (zh) 2018-02-19 2024-11-05 住友制药株式会社 细胞聚集体、细胞聚集体的混合物和它们的制造方法
WO2020022261A1 (ja) 2018-07-23 2020-01-30 国立大学法人京都大学 新規腎前駆細胞マーカーおよびそれを利用した腎前駆細胞の濃縮方法
CA3110661A1 (en) 2018-08-29 2020-03-05 University Of Massachusetts Inhibition of protein kinases to treat friedreich ataxia
WO2020045642A1 (ja) 2018-08-31 2020-03-05 学校法人同志社 眼細胞を保存または培養するための組成物および方法
CN113015429A (zh) 2018-10-02 2021-06-22 学校法人同志社 用于保存角膜内皮细胞的方法和容器
UY38427A (es) 2018-10-26 2020-05-29 Novartis Ag Métodos y composiciones para terapia con células oculares
JP7224001B2 (ja) 2018-12-21 2023-02-17 国立大学法人京都大学 ルブリシン局在軟骨様組織、その製造方法及びそれを含む関節軟骨損傷治療用組成物
WO2020193802A1 (en) 2019-03-28 2020-10-01 Fundación De La Comunidad Valenciana Centro De Investigación Príncipe Felipe Polymeric conjugates and uses thereof
JP7489377B2 (ja) 2019-03-29 2024-05-23 株式会社カネカ 多能性幹細胞を含む細胞集団及びその製造方法
CA3140384A1 (en) 2019-05-15 2020-11-19 Ajinomoto Co., Inc. Method for purifying neural crest cells or corneal epithelial cells
US20230257700A1 (en) 2020-02-27 2023-08-17 Kyoto Prefectural Public University Corporation Functional human corneal endothelial cells and application thereof
US20230348852A1 (en) 2020-04-27 2023-11-02 Novartis Ag Methods and compositions for ocular cell therapy
WO2022149616A1 (ja) 2021-01-08 2022-07-14 国立大学法人京都大学 ネフロン前駆細胞を拡大培養するための培地、ネフロン前駆細胞を拡大培養する方法、腎臓オルガノイドの製造方法
MX2023008141A (es) 2021-01-11 2023-10-20 Incyte Corp Terapia combinada que comprende el inhibidor de la vía de proteínas tirosina cinasas de janus cinasas (jak) y el inhibidor de la proteína cinasa asociada a rho (rock).
KR20230165846A (ko) 2021-04-07 2023-12-05 후지필름 셀룰러 다이내믹스, 인코포레이티드 도파민성 전구세포 및 사용 방법
JP2024519218A (ja) 2021-05-03 2024-05-09 アステラス インスティテュート フォー リジェネレイティブ メディシン 成熟角膜内皮細胞を作製する方法
CA3222761A1 (en) 2021-06-10 2022-12-15 Ajinomoto Co., Inc. Method for producing mesenchymal stem cells
US20240318142A1 (en) 2021-08-11 2024-09-26 Kyoto University Method for producing renal interstitial progenitor cells, erythropoietin-producing cells, and method for producing renin-producing cells
WO2023039588A1 (en) 2021-09-13 2023-03-16 FUJIFILM Cellular Dynamics, Inc. Methods for the production of committed cardiac progenitor cells
WO2023085369A1 (ja) 2021-11-11 2023-05-19 学校法人同志社 角膜内皮細胞の凍結保存製剤およびその製造法
CN118302517A (zh) 2021-11-19 2024-07-05 国立研究开发法人理化学研究所 片状视网膜组织的制造方法
JPWO2023153464A1 (es) 2022-02-09 2023-08-17
WO2024048731A1 (ja) 2022-08-31 2024-03-07 国立大学法人京都大学 ナイーブ型多能性幹細胞の製造方法
WO2024070494A1 (ja) 2022-09-26 2024-04-04 国立大学法人京都大学 膵内胚葉細胞の製造方法
JP2025532957A (ja) 2022-09-30 2025-10-03 フジフィルム セルラー ダイナミクス，インコーポレイテッド 心臓線維芽細胞の作製方法
WO2025224050A1 (en) 2024-04-22 2025-10-30 Institut National de la Santé et de la Recherche Médicale Methods of treatment of patients suffering from hypomelanosis of ito

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US14679A (en) * 1856-04-15 Joel h
US3755332A (en) * 1971-07-01 1973-08-28 Ciba Geigy Corp Substituted 4 indazolaminoquinolines
US4642347A (en) * 1985-05-21 1987-02-10 American Home Products Corporation 3(2-quinolinylalkoxy)phenols
US5245038A (en) * 1987-11-06 1993-09-14 Baxter Diagnostics Inc. Fluorescent poly(arylpyridine) rare earth chelates
IL89029A (en) * 1988-01-29 1993-01-31 Lilly Co Eli Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them
US4952567A (en) * 1988-05-09 1990-08-28 City Of Hope Inhibition of lipogenesis
US6004979A (en) * 1991-02-07 1999-12-21 Hoechst Marion Roussel Nitrogenous bicycles
MX9200299A (es) * 1991-02-07 1992-12-01 Roussel Uclaf Nuevos derivados biciclicos nitrogenados, su procedimiento de preparacion los nuevos compuestos intermedios obtenidos su aplicacion como medicamentos y las composiciones farmaceuticas que los contienen.
JP3531944B2 (ja) * 1991-02-07 2004-05-31 アベンティス・ファーマ・ソシエテ・アノニム 新規のベンジル基で置換された窒素系二環式誘導体及びその製造方法
US5710158A (en) * 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US6645969B1 (en) * 1991-05-10 2003-11-11 Aventis Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
US5721237A (en) * 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
US5245036A (en) * 1992-05-07 1993-09-14 Dowelanco Process for the preparation of 4-phenoxyquinoline compounds
US5972598A (en) * 1992-09-17 1999-10-26 Board Of Trustess Of The University Of Illinois Methods for preventing multidrug resistance in cancer cells
GB9323290D0 (en) * 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
EP1195372A1 (en) * 1994-04-18 2002-04-10 Mitsubishi Pharma Corporation N-heterocyclic substituted benzamide derivatives with antihypertensive activity
US5840695A (en) * 1994-10-07 1998-11-24 Heska Corporation Ectoparasite saliva proteins and apparatus to collect such proteins
GB9514265D0 (en) * 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
US5906819A (en) * 1995-11-20 1999-05-25 Kirin Beer Kabushiki Kaisha Rho target protein Rho-kinase
DE19608653A1 (de) * 1996-03-06 1997-09-11 Thomae Gmbh Dr K Pyrimido[5,4-d]pyrimidine, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
ATE227283T1 (de) * 1996-07-13 2002-11-15 Glaxo Group Ltd Kondensierte heterozyklische verbindungen als protein kinase inhibitoren
EP0956865B2 (en) * 1996-08-12 2010-08-18 Mitsubishi Tanabe Pharma Corporation MEDICINES COMPRISING Rho KINASE INHIBITOR
AR012634A1 (es) * 1997-05-02 2000-11-08 Sugen Inc Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
US5885803A (en) * 1997-06-19 1999-03-23 Incyte Pharmaceuticals, Inc. Disease associated protein kinases
ZA986729B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
RS49779B (sr) * 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
GB9800575D0 (en) * 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
HUP0103386A3 (en) * 1998-08-21 2002-07-29 Parker Hughes Inst St Paul Use of quinazoline derivatives for producing pharmaceutical compositions having jak 3-inhibitor effect
US6184226B1 (en) * 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
DE59913467D1 (en) * 1998-12-23 2006-06-29 Bayer Materialscience Ag Polycarbonate mit niedrigem yellowness-index
GB2345486A (en) * 1999-01-11 2000-07-12 Glaxo Group Ltd Heteroaromatic protein tyrosine kinase inhibitors
UA71945C2 (en) * 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
JP3270834B2 (ja) * 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク 抗がん剤として有用なヘテロ芳香族二環式誘導体
CZ305827B6 (cs) * 1999-02-10 2016-03-30 Astrazeneca Ab Indolové deriváty
US6080747A (en) * 1999-03-05 2000-06-27 Hughes Institute JAK-3 inhibitors for treating allergic disorders
UA73993C2 (uk) * 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
MXPA03005610A (es) * 2000-12-21 2003-10-06 Vertex Pharma Compuestos de pirazol utiles como inhibidores de la proteina cinasa.
MY134783A (en) * 2001-03-23 2007-12-31 Bayer Healthcare Llc Rho-kinase inhibitors
GB0126433D0 (en) * 2001-11-03 2002-01-02 Astrazeneca Ab Compounds
CN100343238C (zh) * 2001-11-03 2007-10-17 阿斯特拉曾尼卡有限公司 用作抗肿瘤药物的喹唑啉衍生物
GB0128108D0 (en) * 2001-11-23 2002-01-16 Astrazeneca Ab Therapeutic use
CA2472619A1 (en) * 2002-01-10 2003-07-24 Bayer Corporation Fused pyrimidine derivates as rho-kinase inhibitors
ES2298497T3 (es) * 2002-01-23 2008-05-16 Bayer Pharmaceuticals Corporation Inhibidores de quinasa rho.
RU2365588C2 (ru) * 2002-02-01 2009-08-27 Астразенека Аб Хиназолиновые соединения
ES2305744T3 (es) * 2003-03-12 2008-11-01 Millennium Pharmaceuticals, Inc. Derivados de quinazolina como inhibidores e tgf-beta.
GB0318422D0 (en) * 2003-08-06 2003-09-10 Astrazeneca Ab Chemical compounds
DE602006018331D1 (de) * 2005-09-20 2010-12-30 Astrazeneca Ab 4-(1h-indazol-5-ylamino)chinazolinverbindungen als inhibitoren der erbb-rezeptortyrosinkinase zur behandlung von krebs

Also Published As

Publication number Publication date
CY1107475T1 (el) 2013-03-13
JP2004524350A (ja) 2004-08-12
EP1370553B1 (en) 2006-05-10
US20030125344A1 (en) 2003-07-03
WO2002076976A2 (en) 2002-10-03
EP1370553A2 (en) 2003-12-17
CA2441492A1 (en) 2002-10-03
HK1061030A1 (en) 2004-09-03
HN2002000067A (es) 2003-10-24
ATE325795T1 (de) 2006-06-15
ES2264477T3 (es) 2007-01-01
MXPA03008658A (es) 2005-04-11
DK1370553T3 (da) 2006-09-11
AR035791A1 (es) 2004-07-14
PT1370553E (pt) 2006-09-29
MY134783A (en) 2007-12-31
UY27224A1 (es) 2002-10-31
JP4329003B2 (ja) 2009-09-09
TWI261055B (en) 2006-09-01
DE60211317D1 (de) 2006-06-14
US20100137324A1 (en) 2010-06-03
DE60211317T2 (de) 2007-04-12
CA2441492C (en) 2011-08-09
US20060142313A1 (en) 2006-06-29
WO2002076976A3 (en) 2002-12-12
AU2002250394A1 (en) 2002-10-08

Similar Documents

Publication Publication Date Title
PE20021011A1 (es) Derivados quinazolinicos como inhibidores de la rho-quinasa
RU2403251C2 (ru) Производные 2, 4-ди(гетеро)ариламинопиримидина в качестве ингибиторов zap-70
EA200600351A1 (ru) Новые соединения, обладающие ингибирующей активностью в отношении натрийзависимого транспортёра
CY1120169T1 (el) Παραγωγο αμιδιου και φαρμακο
ATE366724T1 (de) Kondensierte heterocyclische derivate
RU2004130488A (ru) Пиримидиновые производные
PE20020858A1 (es) Indanil aminas aciladas
PE20011166A1 (es) Piridinas, pirimidinas, purinonas, pirrolopirimidinonas y pirrolopiridinonas como antagonistas del factor liberador de corticotropina
NO900991L (no) Analogifremgangsmaate for fremstilling av terapeutisk virksomme 2-(l-piperazinyl)-4-fenylcycloalkanopyridin-derivater
NO20021395D0 (no) Kinazolinderivater
RU2004120553A (ru) Производные никотинамида, полезные в качестве р38-ингибиторов
PE20061305A1 (es) Compuestos derivados de fenilacetamidas como inhibidores de proteincinasas
EA200400466A1 (ru) Производные пиперазина с антагонистической активностью к рецептору ccr1
PE20040155A1 (es) Derivados aminoinazoles, procedimiento de preparacion e intermedios de este procedimiento a titulo de medicamentos y composiciones farmaceuticas que los contienen
AR033379A1 (es) Compuestos de difenilurea, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
ATE447560T1 (de) Amidderivat
PE20040667A1 (es) Derivados de cinamida
ATE422884T1 (de) Verwendung von substituierten cyanopyrrolidinen zur behandlung von hyperlipidämie
RU2001135802A (ru) Антагонисты рецептора брадикинина
DK1157998T3 (da) Heterocykliske forbindelser, mellemprodukter derfor og elastaseinhibitorer
EP1465488A4 (en) ARYLAMINES AS INHIBITORS OF THE BINDING OF CHEMOKINE A US28
RU97115107A (ru) Бициклические производные изотиомочевины, применяемые в терапии
EA201070813A1 (ru) Производные n-гетероциклоимидазо[1,2-а]пиридин-2-карбоксамидов, их получение и применение в терапии
RU2004129734A (ru) Производные изохинолона
HUP0400854A2 (hu) Tri- és tetraaza-acenaftilén-származékok mint CRF receptor antagonisták és ezeket tartalmazó gyógyszerkészítmények

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed